Literature DB >> 7513208

Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.

T Tsujimura1, T Furitsu, M Morimoto, K Isozaki, S Nomura, Y Matsuzawa, Y Kitamura, Y Kanakura.   

Abstract

The c-kit proto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in hematopoiesis, especially in mast cell growth and differentiation. Although a number of dominant loss-of-function mutations of c-kit gene have been well characterized in mice, rats, and humans, little is known about the c-kit mutations contributing to ligand-independent activation of the c-kit receptor tyrosine kinase (KIT). In a murine mastocytoma cell line, P-815, KIT has been found to be constitutively phosphorylated on tyrosine and activated in a ligand-independent manner. Sequencing of the whole coding region of c-kit cDNA showed that c-kit cDNA of P-815 cells carries a point mutation in codon 814, resulting in amino acid substitution of Tyr for Asp. Murine wild-type c-kit cDNA and mutant-type c-kit cDNA encoding Tyr in codon 814 were expressed in cells of a human embryonic kidney cell line, 293T. In the transfected cells, mutant-form KITTyr814 was strikingly phosphorylated on tyrosine and activated in immune complex kinase reaction regardless of stimulation with a ligand for KIT (stem cell factor), whereas tyrosine phosphorylation and activation was barely detectable in wild-form KIT. The data presented here provide evidence for a novel activating mutation of c-kit gene that might be involved in neoplastic growth or oncogenesis of some cell types, including mast cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513208

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Authors:  Youl-Nam Lee; Stephanie Brandal; Pierre Noel; Erik Wentzel; Joshua T Mendell; Michael A McDevitt; Reuben Kapur; Melody Carter; Dean D Metcalfe; Clifford M Takemoto
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

2.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authors:  M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.

Authors:  L P Lam; R Y Chow; S A Berger
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

5.  SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.

Authors:  M Kozlowski; L Larose; F Lee; D M Le; R Rottapel; K A Siminovitch
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

6.  Oncostatin M inhibits proliferation of rat oval cells, OC15-5, inducing differentiation into hepatocytes.

Authors:  Atsuhito Okaya; Junichi Kitanaka; Nobue Kitanaka; Makoto Satake; Yuna Kim; Kunihiko Terada; Toshihiro Sugiyama; Motohiko Takemura; Jiro Fujimoto; Nobuyuki Terada; Atsushi Miyajima; Tohru Tsujimura
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Authors:  H Nagata; A S Worobec; C K Oh; B A Chowdhury; S Tannenbaum; Y Suzuki; D D Metcalfe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

10.  Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

Authors:  Andreas Schirmer; Jonathan Kennedy; Sumati Murli; Ralph Reid; Daniel V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.